Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jul 29;10(1):223.
doi: 10.1186/s13287-019-1328-4.

Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF)

Roberto Lonardi  1 , Nicola Leone  2 , Stefano Gennai  1 , Giulia Trevisi Borsari  1 , Tea Covic  1 , Roberto Silingardi  1
Affiliations
Randomized Controlled Trial

Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF)

Roberto Lonardi et al. Stem Cell Res Ther. .

Abstract

Background: The diabetic foot ulcer (DFU) is one of the most prevalent complications of diabetes mellitus and often develops severe effects that can lead to amputation. A non-healing "minor" amputation often precedes a major amputation resulting in a negative impact on the function and quality of life of the patients. Stem cell-based therapies have emerged as a promising option to improve healing, and the adipose tissue is an abundant and easy to access source. The injection of autologous micro-fragmented adipose tissue at the amputation stump of a diabetic population undergoing a lower limb minor amputation was evaluated and compared with the standard care.

Methods: In this randomized controlled trial with two arms (parallel assignment) and no masking, 114 patients undergoing a lower limb minor amputation were randomized to standard of care or to micro-fragmented adipose tissue injection prepared using a minimal manipulation technique (Lipogems®) in a closed system. Clinical outcomes were determined monthly up to 6 months. Primary endpoint of the study was the evaluation of the healing rate and time after the minor amputation. Secondary endpoints included the assessment of safety, feasibility, technical success, relapse rate, skin tropism, and intensity of pain.

Results: At 6 months, 80% of the micro-fragmented adipose tissue-treated feet healed and 20% failed as compared with the control group where 46% healed and 54% failed (p = 0.0064). No treatment-related adverse events nor relapses were documented, and technical success was achieved in all cases. The skin tropism was improved in the treatment group, and the pain scale did not differ between the two groups.

Conclusion: The results of this randomized controlled trial suggest that the local injection of autologous micro-fragmented adipose tissue is a safe and valid therapeutic option able to improve healing rate following minor amputations of irreversible DFU. The technique overcomes several stem cell therapy-related criticisms and its potential in wound care should be better evaluated and the therapeutic indications could be expanded.

Trial registration: ClinicalTrials.gov number: NCT03276312. Date of registration: September 8, 2017 (retrospectively registered).

Keywords: Adipose tissue; Amputation; Diabetes mellitus; Peripheral arterial disease; Peripheral vascular diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
MiFrAADiF trial flow diagram, inclusion and exclusion criteria
Fig. 2
Fig. 2
Kaplan-Meier showing healing probability over time
Fig. 3
Fig. 3
Kaplan-Meier showing visual analogue scale (VAS) over time
See this image and copyright information in PMC

References

    1. Boulton Andrew JM, Vileikyte Loretta, Ragnarson-Tennvall Gunnel, Apelqvist Jan. The global burden of diabetic foot disease. The Lancet. 2005;366(9498):1719–1724. doi: 10.1016/S0140-6736(05)67698-2. - DOI - PubMed
    1. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision) J. Foot Ankle Surg. 2006;45:S1–S66. doi: 10.1016/S1067-2516(07)60001-5. - DOI - PubMed
    1. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63:3S–21S. doi: 10.1016/j.jvs.2015.10.003. - DOI - PubMed
    1. Snyder RJ, Hanft JR. Diabetic foot ulcers—effects on quality of life, costs, and mortality and the role of standard wound care and advanced-care therapies in healing: a review. Ostomy Wound Manage. 2009;55:28. - PubMed
    1. Thorud JC, Jupiter DC, Lorenzana J, et al. Reoperation and reamputation after transmetatarsal amputation: a systematic review and meta-analysis. J. Foot Ankle Surg. 2016;55:1007–1012. doi: 10.1053/j.jfas.2016.05.011. - DOI - PubMed

Publication types

Associated data